Mash B, Bheekie A, Jones P W
Family Medicine, University of Stellenbosch, PO Box 19063, Tygerberg, Western Cape, South Africa, 7505.
Cochrane Database Syst Rev. 2000;2001(2):CD002160. doi: 10.1002/14651858.CD002160.
To determine therapeutically equivalent doses of inhaled versus oral steroids for adults with chronic asthma.
The Cochrane Airways Group trials register was searched using the terms: (drug delivery systems OR ((nebuli* OR inhal* OR MDI) AND oral*)) AND ( steroid* OR corticosteroid* OR glucocorticoid* OR beclomethasone OR betamethasone OR fluticasone OR cortisone OR dexamethasone OR hydrocortisone OR prednisolone OR prednisone OR triamcinolone).
Randomised controlled trials were selected of at least 4 weeks duration and included patients over the age of 15 years with chronic asthma. Trials compared inhaled steroids and oral prednisolone or prednisone; where the maximum dose for inhaled steroids was 2000 mcg/day and prednisolone 60 mg (on alternate days).
Two independent reviewers screened 1285 titles and abstracts from the electronic search, bibliography searches and other contacts. Of these, 10 trials met previously defined inclusion criteria. Two reviewers independently extracted study characteristics, and outcome measures.
All trials were small and no data could be pooled. Carry-over effects were present in at least one cross-over trial. Data from six trials produced the same pattern, in which prednisolone 7.5-12 mg/day appeared to be as effective as inhaled steroid 300-2000 mcg/day. In two trials, inhaled steroid 300-400 mcg/day was more effective than prednisolone 5 mg/day. All doses of inhaled steroid appeared to be more effective than alternate day doses of prednisolone up to 60 mg on alternate days. Side-effect data were reported too variably to permit comparisons. A 30% incidence was reported in one study in patients receiving prednisolone 5 mg/day, none were reported in patients on inhaled steroids.
REVIEWER'S CONCLUSIONS: A daily dose of prednisolone 7.5-10 mg/day appears to be equivalent to moderate-high dose inhaled corticosteroids. Side-effects may be present on low doses, so if there is no alternative to oral steroids, the lowest effective dose should be prescribed.
确定用于成年慢性哮喘患者的吸入性与口服类固醇的治疗等效剂量。
使用以下检索词检索Cochrane气道组试验注册库:(药物递送系统或((雾化器或吸入或定量吸入器)与口服*))以及(类固醇或皮质类固醇或糖皮质激素*或倍氯米松或倍他米松或氟替卡松或可的松或地塞米松或氢化可的松或泼尼松龙或泼尼松或曲安西龙)。
选择持续时间至少4周的随机对照试验,纳入年龄超过15岁的慢性哮喘患者。试验比较吸入性类固醇与口服泼尼松龙或泼尼松;其中吸入性类固醇的最大剂量为每日2000微克,泼尼松龙为60毫克(隔日服用)。
两名独立的评审员筛选了来自电子检索、参考文献检索及其他渠道的1285篇标题和摘要。其中,10项试验符合先前定义的纳入标准。两名评审员独立提取研究特征和结果指标。
所有试验规模均较小,无法合并数据。至少一项交叉试验存在残留效应。六项试验的数据呈现相同模式,即每日7.5 - 12毫克泼尼松龙似乎与每日300 - 2000微克吸入性类固醇效果相同。在两项试验中,每日300 - 400微克吸入性类固醇比每日5毫克泼尼松龙更有效。所有剂量的吸入性类固醇似乎比隔日服用高达60毫克的泼尼松龙更有效。副作用数据报告差异太大,无法进行比较。一项研究报告接受每日5毫克泼尼松龙治疗的患者中副作用发生率为30%,而吸入性类固醇治疗的患者未报告有副作用。
每日7.5 - 10毫克泼尼松龙似乎等同于中高剂量吸入性皮质类固醇。低剂量时可能存在副作用,因此如果没有替代口服类固醇的药物,应开具最低有效剂量。